Why the study?
Does pentavalent rotavirus vaccine (RV5) administered on an early alternative dosing schedule have comparable safety and immunogenicity to the recommended standard schedule in infants?
Does pentavalent rotavirus vaccine (RV5) administered on an early alternative dosing schedule have comparable safety and immunogenicity to the recommended standard schedule in infants?
An early alternative dosing schedule for the pentavalent rotavirus vaccine warrants further investigation in larger clinical trials.
Answers are grounded in this paper and cite their sources.
Supports neonatal RV5 feasibility in pilot data; leaves open safety and efficacy confirmation in larger trials.
This study compares the safety and immunogenicity of pentavalent rotavirus vaccine (RV5) administered on an alternative schedule (initiated at 2-5 weeks of age) with those of RV5 administered on the recommended standard schedule. Our findings support the future conduct of larger clinical trials to confirm the safety and efficacy of rotavirus vaccination in the neonatal period.
No takes yet. Share an insight, caveat, or question.
Saleh et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: